FDA Wednesday (Sept. 6) finalized guidance outlining when manufacturers of certain human cells, tissues, and cellular and tissue-based products (HCT/Ps) must report when infectious disease testing or donor eligibility determinations are not conducted properly. The final guidance adds more examples and recommendations for manufacturers, appearing to answer requests from industry for additional clarity. FDA said that the included examples reflect the most frequently reported HCT/P deviations, but noted that the examples are not all-inclusive and encouraged continued communication to ensure...